Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Возможности использования современного петлевого диуретика торасемида в комплексной антигипертензивной терапии
Возможности использования современного петлевого диуретика торасемида в комплексной антигипертензивной терапии
Никулина Н.Н., Якушин С.С. Возможности использования современного петлевого диуретика торасемида в комплексной антигипертензивной терапии. Consilium Medicum. 2016; 18 (5): 30–35. DOI: 10.26442/2075-1753_2016.5.30-35
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Диуретики на протяжении нескольких десятилетий остаются неотъемлемой частью антигипертензивной терапии. Место петлевых диуретиков в лечении пациентов с артериальной гипертензией до недавнего времени ограничивалось наличием дополнительных показаний (хронической сердечной недостаточности, хронической болезни почек) либо купированием гипертонического криза. Торасемид позволил расширить возможности использования петлевых диуретиков в комплексной антигипертензивной терапии благодаря эффективному и длительному натрийуретическому действию, дополнительным свойствам (антиальдостероновое, антифибротическое, вазодилатирующее), а также отсутствию синдрома «рикошета» и безопасному метаболическому профилю.
Ключевые слова: артериальная гипертензия, антигипертензивная терапия, диуретики, петлевые диуретики, торасемид, Тригрим.
Key words: arterial hypertension, antihypertensive therapy, diuretics, loop diuretics, torasemid, Trigrim.
Ключевые слова: артериальная гипертензия, антигипертензивная терапия, диуретики, петлевые диуретики, торасемид, Тригрим.
________________________________________________
Key words: arterial hypertension, antihypertensive therapy, diuretics, loop diuretics, torasemid, Trigrim.
Полный текст
Список литературы
1. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31: 1281–357.
2. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (5): 507–20.
3. Лукьянов М.М., Бойцов С.А., Якушин С.С. и др. Сочетанные сердечно-сосудистые заболевания и антигипертензивное лечение у больных артериальной гипертонией в амбулаторно-поликлинической практике (по данным регистра РЕКВАЗА). Рациональная фармакотерапия в кардиологии. 2016; 12 (1): 4–15. / Luk'janov M.M., Bojcov S.A., Jakushin S.S. i dr. Sochetannye serdechno-sosudistye zabolevanija i antigipertenzivnoe lechenie u bol'nyh arterial'noj gipertoniej v ambulatorno-poliklinicheskoj praktike (po dannym registra REKVAZA). Racional'naja farmakoterapija v kardiologii. 2016; 12 (1): 4–15. [in Russian]
4. Сычев Д.А., Умарова А.Р., Богдан З.А. Клинико-фармакологические аспекты применения торасемида при артериальной гипертензии. Кардиология. 2012; 4: 170–6. / Sychev D.A., Umarova A.R., Bogdan Z.A. Kliniko-farmakologicheskie aspekty primenenija torasemida pri arterial'noj gipertenzii. Kardiologija. 2012; 4: 170–6. [in Russian]
5. Кузина Ю.О., Натальская Н.Ю., Морукова Т.А. Определение уровня гликированного гемоглобина (HbA1C) для раннего выявления нарушений углеводного обмена у пациентов с артерильной гипертензией. Наука молодых – Eruditio Juvenium. 2013; 3: 56–9. / Kuzina Ju.O., Natal'skaja N.Ju., Morukova T.A. Opredelenie urovnja glikirovannogo gemoglobina (HbA1C) dlja rannego vyjavlenija narushenij uglevodnogo obmena u pacientov s arteril'noj gipertenziej. Nauka molodyh – Eruditio Juvenium. 2013; 3: 56–9. [in Russian]
6. Карпов Ю.А. Торасемид: рекомендации для клинического применения при хронической сердечной недостаточности и артериальной гипертензии. РМЖ. 2014; 23: 1676–80. / Karpov Ju.A. Torasemid: rekomendacii dlja klinicheskogo primenenija pri hronicheskoj serdechnoj nedostatochnosti i arterial'noj gipertenzii. RMZh. 2014; 23: 1676–80. [in Russian]
7. Masereel B, Ferrari P, Ferrandi M et al. Na+,2Cl-, K+ cotransport system as a marker of antihypertensive activity of new torasemide derivatives. Eur J Pharmacol 1992; 219 (3): 385–94.
8. Преображенский Д.В., Сидоренко Б.А., Вышинская И.Д. и др. Торасемид – революционный петлевой диуретик: особенности фармакологии и клиническая эффективность. Сердце: журнал для практикующих врачей. 2007; 6 (2): 69–74. / Preobrazhenskij D.V., Sidorenko B.A., Vyshinskaja I.D. i dr. Torasemid – revoljucionnyj petlevoj diuretik: osobennosti farmakologii i klinicheskaja jeffektivnost'. Serdce: zhurnal dlja praktikujushhih vrachej. 2007; 6 (2): 69–74. [in Russian]
9. Беленков Ю.Н., Шакарьянц Г.А. Место торасемида в современной терапии хронической сердечной недостаточности. Сердечная недостаточность. 2015; 16 (6): 391–5. / Belenkov Ju.N., Shakar'janc G.A. Mesto torasemida v sovremennoj terapii hronicheskoj serdechnoj nedostatochnosti. Serdechnaja nedostatochnost'. 2015; 16 (6): 391–5. [in Russian]
10. Фомин В.В. Антиальдостероновое действие торасемида: случайность или необходимость? РМЖ. 2012; 14: 693–7. / Fomin V.V. Antial'dosteronovoe dejstvie torasemida: sluchajnost' ili neobhodimost'? RMZh. 2012; 14: 693–7. [in Russian]
11. Lemarie CA, Paradis P, Schiffrin EL. New insights on signalling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med 2008; 86: 673–8.
12. Uchida T, Yananaga K, Nishikawa M et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 205 (2): 145–50.
13. Uchida T, Yananaga K, Kido H et al. Diuretic and vasodilating actions of torasemide. Cardiology 1994; 84 (Suppl. 2): 14–7.
14. Goodfriend TL, Ball DL, Oelkers W, Bahr V. Torasemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): PL45–50.
15. Cosin J, Diez J, TORIC Investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4 (4): 507–13.
16. Подзолков В.И., Родионов А.В. Первичный гиперальдостеронизм: диагностика и лечение. Артериальная гипертензия. 2004; 10 (2): 1–11. / Podzolkov V.I., Rodionov A.V. Pervichnyj giperal'dosteronizm: diagnostika i lechenie. Arterial'naja gipertenzija. 2004; 10 (2): 1–11. [in Russian]
17. Lopez B, Querejeta R, Gonz lez A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43 (11): 2028–35.
18. Lopez B, Gonzalez A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50 (9): 859–67.
19. Шугушев Х.Х., Гаева А. А. Влияние фуросемида и торасемида на вариабельность сердечного ритма и желудочковые аритмии у больных с хронической сердечной недостаточностью, осложнившей течение ишемической болезни сердца: сравнительное нерандомизированное исследование. Рациональная фармакотерапия в кардиологии. 2010; 6 (4): 513–7. / Shugushev H.H., Gaeva A. A. Vlijanie furosemida i torasemida na variabel'nost' serdechnogo ritma i zheludochkovye aritmii u bol'nyh s hronicheskoj serdechnoj nedostatochnost'ju, oslozhnivshej techenie ishemicheskoj bolezni serdca: sravnitel'noe nerandomizirovannoe issledovanie. Racional'naja farmakoterapija v kardiologii. 2010; 6 (4): 513–7. [in Russian]
20. Загравская И.А. Нарушения ритма сердца и электролитный дисбаланс крови при сравнительном лечении хронической сердечной недостаточности петлевыми диуретиками. Российский медико-биологический вестник им. акад. И.П.Павлова. 2010; 2: 78–85. / Zagravskaja I.A. Narushenija ritma serdca i jelektrolitnyj disbalans krovi pri sravnitel'nom lechenii hronicheskoj serdechnoj nedostatochnosti petlevymi diuretikami. Rossijskij mediko-biologicheskij vestnik im. akad. I.P.Pavlova. 2010; 2: 78–85. [in Russian]
21. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 2005; 14 (3): 235–41.
22. Cody RJ. The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease. Am J Cardiol 1997; 80 (9B): 9J–14J.
23. Yamanaga K, Uchida T, Kido H et al. Torasemide, but not furosemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat. J Pharm Pharmacol 1992; 44 (1): 64–5.
24. Young MJ, Lam EY, Rickard AJ. Mineralocorticoid receptor activator and cardiac fibrosis. Clin Sci 2007; 112 (9): 467–75.
25. Bobrie G, Frank M, Azizi M et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012; 30 (8): 1656–64.
26. Мелехов А.В., Рязанцева Е.Е. Новые диуретические препараты в лечении артериальной гипертонии. Атмосфера: новости кардиологии. 2014; 1: 48–52. / Melehov A.V., Rjazanceva E.E. Novye diureticheskie preparaty v lechenii arterial'noj gipertonii. Atmosfera: novosti kardiologii. 2014; 1: 48–52. [in Russian]
27. Friedel H, Buckley MM. Torasemide: а review of its pharmacology and therapeutic potential. Drugs 1991; 41 (1): 81–103.
28. Bоlke T, Achhammer I. Torasemide: review of its pharmacology and therapeutic use. Drug Today 1994; 8: 1–28.
29. Dunn CJ, Fitton A, Brogden RN. Torasemide: an update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49 (1): 121–42.
30. Vormfelde SV, Toliat MR, Schirmer M et al. The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 83: 815–7.
31. Coca A. Effect of torasemide in monotherapy or associated to other antihypertensive drugs on pulse pressure in essential hypertension. Am J Hypertens 2002; 15 (S3): 113A–4A.
32. Ткачева О.Н., Шарашкина Н.В., Новикова И.М., Чухарева Н.А. Сравнительное исследование эффектов торасемида и гидрохлортиазида в комбинированном лечении гипертонической болезни у женщин в постменопаузе. Сердце: журнал для практикующих врачей. 2011; 10 (3): 156–60. / Tkacheva O.N., Sharashkina N.V., Novikova I.M., Chuhareva N.A. Sravnitel'noe issledovanie jeffektov torasemida i gidrohlotiazida v kombinirovannom lechenii gipertonicheskoj bolezni u zhenshhin v postmenopauze. Serdce: zhurnal dlja praktikujushhih vrachej. 2011; 10 (3): 156–60. [in Russian]
33. De Las Fuentes L, Sung YJ, Schwander KL et al. The role of SNP-loop diuretic interactions in hypertension across ethnic groups in HyperGEN. Front Genet 2013; 4: 304.
34. Reyes AJ, Chiesa PD, Santucci MR et al. Hydrochlorothiazide versus a nondiuretic dose of torasemide as once daily antihypertensive monopharmacotherapy in elderly patients; randomized and double-blind study. Prog Pharmacol Clin Pharmacology 1990; 8: 183–209.
35. Boelke T, Piesche L. Influence of 2,5–5 mg torasemide o.d. versus 25–50 mg HCTZ/50-100 triamterene o.d. on serum parameters in elderly patients with mild to moderate hypertension. In: Diuretics IV: Chemistry, Pharmacology and clinical Applications. Amsterdam: Excerpta Medica 1993; p. 279–82.
36. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2,5 mg torasemide o.d. or 50 mg triamterene/25 mg hydrochlorothiazide o.d. Progress in Pharmacology and Clinical Pharmacology 1990; 8: 211–20.
37. Евдокимова А.Г., Коваленко Е.В., Ложкина М.В. и др. Особенности диуретической терапии при хронической сердечной недостаточности. Consilium Medicum. 2016; 18 (1): 60–5. / Evdokimova A.G., Kovalenko E.V., Lozhkina M.V. i dr. Osobennosti diureticheskoj terapii pri hronicheskoj serdechnoj nedostatochnosti. Consilium Medicum. 2016; 18 (1): 60–5. [in Russian]
38. Sato A, Saruta T. Aldosterone escape during angiotensin converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29: 13–21.
39. Berecek KH, Farag A, Bahtiyar G et al. Adding low-dose spironolactone to multidrug regimens for resistant hypertension. Curr Hypertens Rep 2004; 6 (3): 211–2.
40. Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000; 61 (1): 52–60.
41. Правкина Е.А., Никулина Н.Н., Лукьянов М.М. и др. Качество обследования пациентов с артериальной гипертонией в амбулаторно-поликлинических учреждениях. Клин. медицина. 2015: 93 (9): 36–42. / Pravkina E.A., Nikulina N.N., Luk'janov M.M. i dr. Kachestvo obsledovanija pacientov s arterial'noj gipertoniej v ambulatorno-poliklinicheskih uchrezhdenijah. Klin. medicina. 2015: 93 (9): 36–42. [in Russian]
42. MDS pharma services clinical stady report. Comporative, randomized, single-doze, 2-way crossover bioavailability stady of Polpharma S.A. and Roshe (ToremR) 10 mg Torasemide tablets in healthy adalt volunteers under fasting conditions. Protocol N0. AA15312. MDS pharma services project NO. AA15312
2. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (5): 507–20.
3. Luk'janov M.M., Bojcov S.A., Jakushin S.S. i dr. Sochetannye serdechno-sosudistye zabolevanija i antigipertenzivnoe lechenie u bol'nyh arterial'noj gipertoniej v ambulatorno-poliklinicheskoj praktike (po dannym registra REKVAZA). Racional'naja farmakoterapija v kardiologii. 2016; 12 (1): 4–15. [in Russian]
4. Sychev D.A., Umarova A.R., Bogdan Z.A. Kliniko-farmakologicheskie aspekty primenenija torasemida pri arterial'noj gipertenzii. Kardiologija. 2012; 4: 170–6. [in Russian]
5. Kuzina Ju.O., Natal'skaja N.Ju., Morukova T.A. Opredelenie urovnja glikirovannogo gemoglobina (HbA1C) dlja rannego vyjavlenija narushenij uglevodnogo obmena u pacientov s arteril'noj gipertenziej. Nauka molodyh – Eruditio Juvenium. 2013; 3: 56–9. [in Russian]
6. Karpov Ju.A. Torasemid: rekomendacii dlja klinicheskogo primenenija pri hronicheskoj serdechnoj nedostatochnosti i arterial'noj gipertenzii. RMZh. 2014; 23: 1676–80. [in Russian]
7. Masereel B, Ferrari P, Ferrandi M et al. Na+,2Cl-, K+ cotransport system as a marker of antihypertensive activity of new torasemide derivatives. Eur J Pharmacol 1992; 219 (3): 385–94.
8. Preobrazhenskij D.V., Sidorenko B.A., Vyshinskaja I.D. i dr. Torasemid – revoljucionnyj petlevoj diuretik: osobennosti farmakologii i klinicheskaja jeffektivnost'. Serdce: zhurnal dlja praktikujushhih vrachej. 2007; 6 (2): 69–74. [in Russian]
9. Belenkov Ju.N., Shakar'janc G.A. Mesto torasemida v sovremennoj terapii hronicheskoj serdechnoj nedostatochnosti. Serdechnaja nedostatochnost'. 2015; 16 (6): 391–5. [in Russian]
10. Fomin V.V. Antial'dosteronovoe dejstvie torasemida: sluchajnost' ili neobhodimost'? RMZh. 2012; 14: 693–7. [in Russian]
11. Lemarie CA, Paradis P, Schiffrin EL. New insights on signalling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med 2008; 86: 673–8.
12. Uchida T, Yananaga K, Nishikawa M et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 205 (2): 145–50.
13. Uchida T, Yananaga K, Kido H et al. Diuretic and vasodilating actions of torasemide. Cardiology 1994; 84 (Suppl. 2): 14–7.
14. Goodfriend TL, Ball DL, Oelkers W, Bahr V. Torasemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): PL45–50.
15. Cosin J, Diez J, TORIC Investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4 (4): 507–13.
16. Podzolkov V.I., Rodionov A.V. Pervichnyj giperal'dosteronizm: diagnostika i lechenie. Arterial'naja gipertenzija. 2004; 10 (2): 1–11. [in Russian]
17. Lopez B, Querejeta R, Gonz lez A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43 (11): 2028–35.
18. Lopez B, Gonzalez A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50 (9): 859–67.
19. Shugushev H.H., Gaeva A. A. Vlijanie furosemida i torasemida na variabel'nost' serdechnogo ritma i zheludochkovye aritmii u bol'nyh s hronicheskoj serdechnoj nedostatochnost'ju, oslozhnivshej techenie ishemicheskoj bolezni serdca: sravnitel'noe nerandomizirovannoe issledovanie. Racional'naja farmakoterapija v kardiologii. 2010; 6 (4): 513–7. [in Russian]
20. Zagravskaja I.A. Narushenija ritma serdca i jelektrolitnyj disbalans krovi pri sravnitel'nom lechenii hronicheskoj serdechnoj nedostatochnosti petlevymi diuretikami. Rossijskij mediko-biologicheskij vestnik im. akad. I.P.Pavlova. 2010; 2: 78–85. [in Russian]
21. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 2005; 14 (3): 235–41.
22. Cody RJ. The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease. Am J Cardiol 1997; 80 (9B): 9J–14J.
23. Yamanaga K, Uchida T, Kido H et al. Torasemide, but not furosemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat. J Pharm Pharmacol 1992; 44 (1): 64–5.
24. Young MJ, Lam EY, Rickard AJ. Mineralocorticoid receptor activator and cardiac fibrosis. Clin Sci 2007; 112 (9): 467–75.
25. Bobrie G, Frank M, Azizi M et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012; 30 (8): 1656–64.
26. Melehov A.V., Rjazanceva E.E. Novye diureticheskie preparaty v lechenii arterial'noj gipertonii. Atmosfera: novosti kardiologii. 2014; 1: 48–52. [in Russian]
27. Friedel H, Buckley MM. Torasemide: а review of its pharmacology and therapeutic potential. Drugs 1991; 41 (1): 81–103.
28. Bоlke T, Achhammer I. Torasemide: review of its pharmacology and therapeutic use. Drug Today 1994; 8: 1–28.
29. Dunn CJ, Fitton A, Brogden RN. Torasemide: an update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49 (1): 121–42.
30. Vormfelde SV, Toliat MR, Schirmer M et al. The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 83: 815–7.
31. Coca A. Effect of torasemide in monotherapy or associated to other antihypertensive drugs on pulse pressure in essential hypertension. Am J Hypertens 2002; 15 (S3): 113A–4A.
32. Tkacheva O.N., Sharashkina N.V., Novikova I.M., Chuhareva N.A. Sravnitel'noe issledovanie jeffektov torasemida i gidrohlotiazida v kombinirovannom lechenii gipertonicheskoj bolezni u zhenshhin v postmenopauze. Serdce: zhurnal dlja praktikujushhih vrachej. 2011; 10 (3): 156–60. [in Russian]
33. De Las Fuentes L, Sung YJ, Schwander KL et al. The role of SNP-loop diuretic interactions in hypertension across ethnic groups in HyperGEN. Front Genet 2013; 4: 304.
34. Reyes AJ, Chiesa PD, Santucci MR et al. Hydrochlorothiazide versus a nondiuretic dose of torasemide as once daily antihypertensive monopharmacotherapy in elderly patients; randomized and double-blind study. Prog Pharmacol Clin Pharmacology 1990; 8: 183–209.
35. Boelke T, Piesche L. Influence of 2,5–5 mg torasemide o.d. versus 25–50 mg HCTZ/50-100 triamterene o.d. on serum parameters in elderly patients with mild to moderate hypertension. In: Diuretics IV: Chemistry, Pharmacology and clinical Applications. Amsterdam: Excerpta Medica 1993; p. 279–82.
36. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2,5 mg torasemide o.d. or 50 mg triamterene/25 mg hydrochlorothiazide o.d. Progress in Pharmacology and Clinical Pharmacology 1990; 8: 211–20.
37. Evdokimova A.G., Kovalenko E.V., Lozhkina M.V. i dr. Osobennosti diureticheskoj terapii pri hronicheskoj serdechnoj nedostatochnosti. Consilium Medicum. 2016; 18 (1): 60–5. [in Russian]
38. Sato A, Saruta T. Aldosterone escape during angiotensin converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29: 13–21.
39. Berecek KH, Farag A, Bahtiyar G et al. Adding low-dose spironolactone to multidrug regimens for resistant hypertension. Curr Hypertens Rep 2004; 6 (3): 211–2.
40. Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000; 61 (1): 52–60.
41. Pravkina E.A., Nikulina N.N., Luk'janov M.M. i dr. Kachestvo obsledovanija pacientov s arterial'noj gipertoniej v ambulatorno-poliklinicheskih uchrezhdenijah. Klin. medicina. 2015: 93 (9): 36–42. [in Russian]
42. MDS pharma services clinical stady report. Comporative, randomized, single-doze, 2-way crossover bioavailability stady of Polpharma S.A. and Roshe (ToremR) 10 mg Torasemide tablets in healthy adalt volunteers under fasting conditions. Protocol N0. AA15312. MDS pharma services project NO. AA15312
2. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (5): 507–20.
3. Лукьянов М.М., Бойцов С.А., Якушин С.С. и др. Сочетанные сердечно-сосудистые заболевания и антигипертензивное лечение у больных артериальной гипертонией в амбулаторно-поликлинической практике (по данным регистра РЕКВАЗА). Рациональная фармакотерапия в кардиологии. 2016; 12 (1): 4–15. / Luk'janov M.M., Bojcov S.A., Jakushin S.S. i dr. Sochetannye serdechno-sosudistye zabolevanija i antigipertenzivnoe lechenie u bol'nyh arterial'noj gipertoniej v ambulatorno-poliklinicheskoj praktike (po dannym registra REKVAZA). Racional'naja farmakoterapija v kardiologii. 2016; 12 (1): 4–15. [in Russian]
4. Сычев Д.А., Умарова А.Р., Богдан З.А. Клинико-фармакологические аспекты применения торасемида при артериальной гипертензии. Кардиология. 2012; 4: 170–6. / Sychev D.A., Umarova A.R., Bogdan Z.A. Kliniko-farmakologicheskie aspekty primenenija torasemida pri arterial'noj gipertenzii. Kardiologija. 2012; 4: 170–6. [in Russian]
5. Кузина Ю.О., Натальская Н.Ю., Морукова Т.А. Определение уровня гликированного гемоглобина (HbA1C) для раннего выявления нарушений углеводного обмена у пациентов с артерильной гипертензией. Наука молодых – Eruditio Juvenium. 2013; 3: 56–9. / Kuzina Ju.O., Natal'skaja N.Ju., Morukova T.A. Opredelenie urovnja glikirovannogo gemoglobina (HbA1C) dlja rannego vyjavlenija narushenij uglevodnogo obmena u pacientov s arteril'noj gipertenziej. Nauka molodyh – Eruditio Juvenium. 2013; 3: 56–9. [in Russian]
6. Карпов Ю.А. Торасемид: рекомендации для клинического применения при хронической сердечной недостаточности и артериальной гипертензии. РМЖ. 2014; 23: 1676–80. / Karpov Ju.A. Torasemid: rekomendacii dlja klinicheskogo primenenija pri hronicheskoj serdechnoj nedostatochnosti i arterial'noj gipertenzii. RMZh. 2014; 23: 1676–80. [in Russian]
7. Masereel B, Ferrari P, Ferrandi M et al. Na+,2Cl-, K+ cotransport system as a marker of antihypertensive activity of new torasemide derivatives. Eur J Pharmacol 1992; 219 (3): 385–94.
8. Преображенский Д.В., Сидоренко Б.А., Вышинская И.Д. и др. Торасемид – революционный петлевой диуретик: особенности фармакологии и клиническая эффективность. Сердце: журнал для практикующих врачей. 2007; 6 (2): 69–74. / Preobrazhenskij D.V., Sidorenko B.A., Vyshinskaja I.D. i dr. Torasemid – revoljucionnyj petlevoj diuretik: osobennosti farmakologii i klinicheskaja jeffektivnost'. Serdce: zhurnal dlja praktikujushhih vrachej. 2007; 6 (2): 69–74. [in Russian]
9. Беленков Ю.Н., Шакарьянц Г.А. Место торасемида в современной терапии хронической сердечной недостаточности. Сердечная недостаточность. 2015; 16 (6): 391–5. / Belenkov Ju.N., Shakar'janc G.A. Mesto torasemida v sovremennoj terapii hronicheskoj serdechnoj nedostatochnosti. Serdechnaja nedostatochnost'. 2015; 16 (6): 391–5. [in Russian]
10. Фомин В.В. Антиальдостероновое действие торасемида: случайность или необходимость? РМЖ. 2012; 14: 693–7. / Fomin V.V. Antial'dosteronovoe dejstvie torasemida: sluchajnost' ili neobhodimost'? RMZh. 2012; 14: 693–7. [in Russian]
11. Lemarie CA, Paradis P, Schiffrin EL. New insights on signalling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med 2008; 86: 673–8.
12. Uchida T, Yananaga K, Nishikawa M et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 205 (2): 145–50.
13. Uchida T, Yananaga K, Kido H et al. Diuretic and vasodilating actions of torasemide. Cardiology 1994; 84 (Suppl. 2): 14–7.
14. Goodfriend TL, Ball DL, Oelkers W, Bahr V. Torasemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): PL45–50.
15. Cosin J, Diez J, TORIC Investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4 (4): 507–13.
16. Подзолков В.И., Родионов А.В. Первичный гиперальдостеронизм: диагностика и лечение. Артериальная гипертензия. 2004; 10 (2): 1–11. / Podzolkov V.I., Rodionov A.V. Pervichnyj giperal'dosteronizm: diagnostika i lechenie. Arterial'naja gipertenzija. 2004; 10 (2): 1–11. [in Russian]
17. Lopez B, Querejeta R, Gonz lez A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43 (11): 2028–35.
18. Lopez B, Gonzalez A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50 (9): 859–67.
19. Шугушев Х.Х., Гаева А. А. Влияние фуросемида и торасемида на вариабельность сердечного ритма и желудочковые аритмии у больных с хронической сердечной недостаточностью, осложнившей течение ишемической болезни сердца: сравнительное нерандомизированное исследование. Рациональная фармакотерапия в кардиологии. 2010; 6 (4): 513–7. / Shugushev H.H., Gaeva A. A. Vlijanie furosemida i torasemida na variabel'nost' serdechnogo ritma i zheludochkovye aritmii u bol'nyh s hronicheskoj serdechnoj nedostatochnost'ju, oslozhnivshej techenie ishemicheskoj bolezni serdca: sravnitel'noe nerandomizirovannoe issledovanie. Racional'naja farmakoterapija v kardiologii. 2010; 6 (4): 513–7. [in Russian]
20. Загравская И.А. Нарушения ритма сердца и электролитный дисбаланс крови при сравнительном лечении хронической сердечной недостаточности петлевыми диуретиками. Российский медико-биологический вестник им. акад. И.П.Павлова. 2010; 2: 78–85. / Zagravskaja I.A. Narushenija ritma serdca i jelektrolitnyj disbalans krovi pri sravnitel'nom lechenii hronicheskoj serdechnoj nedostatochnosti petlevymi diuretikami. Rossijskij mediko-biologicheskij vestnik im. akad. I.P.Pavlova. 2010; 2: 78–85. [in Russian]
21. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 2005; 14 (3): 235–41.
22. Cody RJ. The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease. Am J Cardiol 1997; 80 (9B): 9J–14J.
23. Yamanaga K, Uchida T, Kido H et al. Torasemide, but not furosemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat. J Pharm Pharmacol 1992; 44 (1): 64–5.
24. Young MJ, Lam EY, Rickard AJ. Mineralocorticoid receptor activator and cardiac fibrosis. Clin Sci 2007; 112 (9): 467–75.
25. Bobrie G, Frank M, Azizi M et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012; 30 (8): 1656–64.
26. Мелехов А.В., Рязанцева Е.Е. Новые диуретические препараты в лечении артериальной гипертонии. Атмосфера: новости кардиологии. 2014; 1: 48–52. / Melehov A.V., Rjazanceva E.E. Novye diureticheskie preparaty v lechenii arterial'noj gipertonii. Atmosfera: novosti kardiologii. 2014; 1: 48–52. [in Russian]
27. Friedel H, Buckley MM. Torasemide: а review of its pharmacology and therapeutic potential. Drugs 1991; 41 (1): 81–103.
28. Bоlke T, Achhammer I. Torasemide: review of its pharmacology and therapeutic use. Drug Today 1994; 8: 1–28.
29. Dunn CJ, Fitton A, Brogden RN. Torasemide: an update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49 (1): 121–42.
30. Vormfelde SV, Toliat MR, Schirmer M et al. The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 83: 815–7.
31. Coca A. Effect of torasemide in monotherapy or associated to other antihypertensive drugs on pulse pressure in essential hypertension. Am J Hypertens 2002; 15 (S3): 113A–4A.
32. Ткачева О.Н., Шарашкина Н.В., Новикова И.М., Чухарева Н.А. Сравнительное исследование эффектов торасемида и гидрохлортиазида в комбинированном лечении гипертонической болезни у женщин в постменопаузе. Сердце: журнал для практикующих врачей. 2011; 10 (3): 156–60. / Tkacheva O.N., Sharashkina N.V., Novikova I.M., Chuhareva N.A. Sravnitel'noe issledovanie jeffektov torasemida i gidrohlotiazida v kombinirovannom lechenii gipertonicheskoj bolezni u zhenshhin v postmenopauze. Serdce: zhurnal dlja praktikujushhih vrachej. 2011; 10 (3): 156–60. [in Russian]
33. De Las Fuentes L, Sung YJ, Schwander KL et al. The role of SNP-loop diuretic interactions in hypertension across ethnic groups in HyperGEN. Front Genet 2013; 4: 304.
34. Reyes AJ, Chiesa PD, Santucci MR et al. Hydrochlorothiazide versus a nondiuretic dose of torasemide as once daily antihypertensive monopharmacotherapy in elderly patients; randomized and double-blind study. Prog Pharmacol Clin Pharmacology 1990; 8: 183–209.
35. Boelke T, Piesche L. Influence of 2,5–5 mg torasemide o.d. versus 25–50 mg HCTZ/50-100 triamterene o.d. on serum parameters in elderly patients with mild to moderate hypertension. In: Diuretics IV: Chemistry, Pharmacology and clinical Applications. Amsterdam: Excerpta Medica 1993; p. 279–82.
36. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2,5 mg torasemide o.d. or 50 mg triamterene/25 mg hydrochlorothiazide o.d. Progress in Pharmacology and Clinical Pharmacology 1990; 8: 211–20.
37. Евдокимова А.Г., Коваленко Е.В., Ложкина М.В. и др. Особенности диуретической терапии при хронической сердечной недостаточности. Consilium Medicum. 2016; 18 (1): 60–5. / Evdokimova A.G., Kovalenko E.V., Lozhkina M.V. i dr. Osobennosti diureticheskoj terapii pri hronicheskoj serdechnoj nedostatochnosti. Consilium Medicum. 2016; 18 (1): 60–5. [in Russian]
38. Sato A, Saruta T. Aldosterone escape during angiotensin converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29: 13–21.
39. Berecek KH, Farag A, Bahtiyar G et al. Adding low-dose spironolactone to multidrug regimens for resistant hypertension. Curr Hypertens Rep 2004; 6 (3): 211–2.
40. Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000; 61 (1): 52–60.
41. Правкина Е.А., Никулина Н.Н., Лукьянов М.М. и др. Качество обследования пациентов с артериальной гипертонией в амбулаторно-поликлинических учреждениях. Клин. медицина. 2015: 93 (9): 36–42. / Pravkina E.A., Nikulina N.N., Luk'janov M.M. i dr. Kachestvo obsledovanija pacientov s arterial'noj gipertoniej v ambulatorno-poliklinicheskih uchrezhdenijah. Klin. medicina. 2015: 93 (9): 36–42. [in Russian]
42. MDS pharma services clinical stady report. Comporative, randomized, single-doze, 2-way crossover bioavailability stady of Polpharma S.A. and Roshe (ToremR) 10 mg Torasemide tablets in healthy adalt volunteers under fasting conditions. Protocol N0. AA15312. MDS pharma services project NO. AA15312
________________________________________________
2. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (5): 507–20.
3. Luk'janov M.M., Bojcov S.A., Jakushin S.S. i dr. Sochetannye serdechno-sosudistye zabolevanija i antigipertenzivnoe lechenie u bol'nyh arterial'noj gipertoniej v ambulatorno-poliklinicheskoj praktike (po dannym registra REKVAZA). Racional'naja farmakoterapija v kardiologii. 2016; 12 (1): 4–15. [in Russian]
4. Sychev D.A., Umarova A.R., Bogdan Z.A. Kliniko-farmakologicheskie aspekty primenenija torasemida pri arterial'noj gipertenzii. Kardiologija. 2012; 4: 170–6. [in Russian]
5. Kuzina Ju.O., Natal'skaja N.Ju., Morukova T.A. Opredelenie urovnja glikirovannogo gemoglobina (HbA1C) dlja rannego vyjavlenija narushenij uglevodnogo obmena u pacientov s arteril'noj gipertenziej. Nauka molodyh – Eruditio Juvenium. 2013; 3: 56–9. [in Russian]
6. Karpov Ju.A. Torasemid: rekomendacii dlja klinicheskogo primenenija pri hronicheskoj serdechnoj nedostatochnosti i arterial'noj gipertenzii. RMZh. 2014; 23: 1676–80. [in Russian]
7. Masereel B, Ferrari P, Ferrandi M et al. Na+,2Cl-, K+ cotransport system as a marker of antihypertensive activity of new torasemide derivatives. Eur J Pharmacol 1992; 219 (3): 385–94.
8. Preobrazhenskij D.V., Sidorenko B.A., Vyshinskaja I.D. i dr. Torasemid – revoljucionnyj petlevoj diuretik: osobennosti farmakologii i klinicheskaja jeffektivnost'. Serdce: zhurnal dlja praktikujushhih vrachej. 2007; 6 (2): 69–74. [in Russian]
9. Belenkov Ju.N., Shakar'janc G.A. Mesto torasemida v sovremennoj terapii hronicheskoj serdechnoj nedostatochnosti. Serdechnaja nedostatochnost'. 2015; 16 (6): 391–5. [in Russian]
10. Fomin V.V. Antial'dosteronovoe dejstvie torasemida: sluchajnost' ili neobhodimost'? RMZh. 2012; 14: 693–7. [in Russian]
11. Lemarie CA, Paradis P, Schiffrin EL. New insights on signalling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med 2008; 86: 673–8.
12. Uchida T, Yananaga K, Nishikawa M et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 205 (2): 145–50.
13. Uchida T, Yananaga K, Kido H et al. Diuretic and vasodilating actions of torasemide. Cardiology 1994; 84 (Suppl. 2): 14–7.
14. Goodfriend TL, Ball DL, Oelkers W, Bahr V. Torasemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): PL45–50.
15. Cosin J, Diez J, TORIC Investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4 (4): 507–13.
16. Podzolkov V.I., Rodionov A.V. Pervichnyj giperal'dosteronizm: diagnostika i lechenie. Arterial'naja gipertenzija. 2004; 10 (2): 1–11. [in Russian]
17. Lopez B, Querejeta R, Gonz lez A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43 (11): 2028–35.
18. Lopez B, Gonzalez A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50 (9): 859–67.
19. Shugushev H.H., Gaeva A. A. Vlijanie furosemida i torasemida na variabel'nost' serdechnogo ritma i zheludochkovye aritmii u bol'nyh s hronicheskoj serdechnoj nedostatochnost'ju, oslozhnivshej techenie ishemicheskoj bolezni serdca: sravnitel'noe nerandomizirovannoe issledovanie. Racional'naja farmakoterapija v kardiologii. 2010; 6 (4): 513–7. [in Russian]
20. Zagravskaja I.A. Narushenija ritma serdca i jelektrolitnyj disbalans krovi pri sravnitel'nom lechenii hronicheskoj serdechnoj nedostatochnosti petlevymi diuretikami. Rossijskij mediko-biologicheskij vestnik im. akad. I.P.Pavlova. 2010; 2: 78–85. [in Russian]
21. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 2005; 14 (3): 235–41.
22. Cody RJ. The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease. Am J Cardiol 1997; 80 (9B): 9J–14J.
23. Yamanaga K, Uchida T, Kido H et al. Torasemide, but not furosemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat. J Pharm Pharmacol 1992; 44 (1): 64–5.
24. Young MJ, Lam EY, Rickard AJ. Mineralocorticoid receptor activator and cardiac fibrosis. Clin Sci 2007; 112 (9): 467–75.
25. Bobrie G, Frank M, Azizi M et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012; 30 (8): 1656–64.
26. Melehov A.V., Rjazanceva E.E. Novye diureticheskie preparaty v lechenii arterial'noj gipertonii. Atmosfera: novosti kardiologii. 2014; 1: 48–52. [in Russian]
27. Friedel H, Buckley MM. Torasemide: а review of its pharmacology and therapeutic potential. Drugs 1991; 41 (1): 81–103.
28. Bоlke T, Achhammer I. Torasemide: review of its pharmacology and therapeutic use. Drug Today 1994; 8: 1–28.
29. Dunn CJ, Fitton A, Brogden RN. Torasemide: an update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49 (1): 121–42.
30. Vormfelde SV, Toliat MR, Schirmer M et al. The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 83: 815–7.
31. Coca A. Effect of torasemide in monotherapy or associated to other antihypertensive drugs on pulse pressure in essential hypertension. Am J Hypertens 2002; 15 (S3): 113A–4A.
32. Tkacheva O.N., Sharashkina N.V., Novikova I.M., Chuhareva N.A. Sravnitel'noe issledovanie jeffektov torasemida i gidrohlotiazida v kombinirovannom lechenii gipertonicheskoj bolezni u zhenshhin v postmenopauze. Serdce: zhurnal dlja praktikujushhih vrachej. 2011; 10 (3): 156–60. [in Russian]
33. De Las Fuentes L, Sung YJ, Schwander KL et al. The role of SNP-loop diuretic interactions in hypertension across ethnic groups in HyperGEN. Front Genet 2013; 4: 304.
34. Reyes AJ, Chiesa PD, Santucci MR et al. Hydrochlorothiazide versus a nondiuretic dose of torasemide as once daily antihypertensive monopharmacotherapy in elderly patients; randomized and double-blind study. Prog Pharmacol Clin Pharmacology 1990; 8: 183–209.
35. Boelke T, Piesche L. Influence of 2,5–5 mg torasemide o.d. versus 25–50 mg HCTZ/50-100 triamterene o.d. on serum parameters in elderly patients with mild to moderate hypertension. In: Diuretics IV: Chemistry, Pharmacology and clinical Applications. Amsterdam: Excerpta Medica 1993; p. 279–82.
36. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2,5 mg torasemide o.d. or 50 mg triamterene/25 mg hydrochlorothiazide o.d. Progress in Pharmacology and Clinical Pharmacology 1990; 8: 211–20.
37. Evdokimova A.G., Kovalenko E.V., Lozhkina M.V. i dr. Osobennosti diureticheskoj terapii pri hronicheskoj serdechnoj nedostatochnosti. Consilium Medicum. 2016; 18 (1): 60–5. [in Russian]
38. Sato A, Saruta T. Aldosterone escape during angiotensin converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29: 13–21.
39. Berecek KH, Farag A, Bahtiyar G et al. Adding low-dose spironolactone to multidrug regimens for resistant hypertension. Curr Hypertens Rep 2004; 6 (3): 211–2.
40. Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000; 61 (1): 52–60.
41. Pravkina E.A., Nikulina N.N., Luk'janov M.M. i dr. Kachestvo obsledovanija pacientov s arterial'noj gipertoniej v ambulatorno-poliklinicheskih uchrezhdenijah. Klin. medicina. 2015: 93 (9): 36–42. [in Russian]
42. MDS pharma services clinical stady report. Comporative, randomized, single-doze, 2-way crossover bioavailability stady of Polpharma S.A. and Roshe (ToremR) 10 mg Torasemide tablets in healthy adalt volunteers under fasting conditions. Protocol N0. AA15312. MDS pharma services project NO. AA15312
Авторы
Н.Н.Никулина*, С.С.Якушин
ГБОУ ВПО Рязанский государственный медицинский университет им. акад. И.П.Павлова Минздрава России. 390026, Россия, Рязань, ул. Высоковольтная, д. 9
*Natalia.Nikulina@mail.ru
ГБОУ ВПО Рязанский государственный медицинский университет им. акад. И.П.Павлова Минздрава России. 390026, Россия, Рязань, ул. Высоковольтная, д. 9
*Natalia.Nikulina@mail.ru
________________________________________________
N.N.Nikulina*, S.S.Yakushin
I.P.Pavlov Ryazan State Medical University of the Ministry of Health of the Russian Federation. 390026, Russian Federation, Ryazan, ul. Vysokovol'tnaia, d. 9
*Natalia.Nikulina@mail.ru
I.P.Pavlov Ryazan State Medical University of the Ministry of Health of the Russian Federation. 390026, Russian Federation, Ryazan, ul. Vysokovol'tnaia, d. 9
*Natalia.Nikulina@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.